Using ‘omic and digital technologies toward better fasciolosis control. In Australia, liver fluke disease caused by Fasciola hepatica causes major economic losses to livestock production. Triclabendazole is the most effective drug for parasite control, however, resistance to this drug has emerged and continues to spread in Australia. This project expects to create a novel resource to identify new drug targets, generate new knowledge about the genetic composition of F. hepatica populations and un ....Using ‘omic and digital technologies toward better fasciolosis control. In Australia, liver fluke disease caused by Fasciola hepatica causes major economic losses to livestock production. Triclabendazole is the most effective drug for parasite control, however, resistance to this drug has emerged and continues to spread in Australia. This project expects to create a novel resource to identify new drug targets, generate new knowledge about the genetic composition of F. hepatica populations and unravel the genetic determinants underlying triclabendazole resistance. The curation of functionally-annotated genetic data for F. hepatica populations will underpin the development of diagnostic tests, drugs and vaccines to deliver a new generation of intervention strategies to control liver fluke disease.Read moreRead less
A next-generation whole parasite bovine Babesia vaccine. . In Australia, Babesia parasites cause most of the severe and often fatal cases of cattle-tick fever, a globally significant tick-borne disease. It can be prevented by a live-attenuated parasite vaccine which has critical limitations of a 4-day shelf-life and risk of severe disease if administered to adult cattle. This project aims to evaluate in cattle a novel whole parasite Babesia bovis vaccine that cannot cause disease and can be pres ....A next-generation whole parasite bovine Babesia vaccine. . In Australia, Babesia parasites cause most of the severe and often fatal cases of cattle-tick fever, a globally significant tick-borne disease. It can be prevented by a live-attenuated parasite vaccine which has critical limitations of a 4-day shelf-life and risk of severe disease if administered to adult cattle. This project aims to evaluate in cattle a novel whole parasite Babesia bovis vaccine that cannot cause disease and can be preserved as an off-the-shelf product without losing efficacy. The expected outcome is a significantly improved vaccine for a major infectious disease that affects primary food production. As the disease imposes a major economic burden, it will have great benefit for the Australian livestock industry.
Read moreRead less